Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma
- PMID: 16985695
- PMCID: PMC1476038
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma
Abstract
The search continues for better tumor markers to improve the rate of detection of transitional cell carcinoma (TCC) more quickly in larger populations and to predict the possibility of disease recurrence. Among several new tests currently being screened, telomerase and hyaluronic acid/hyaluronidase (HA/HAase) have shown sensitivity and specificity equal to or better than cytology, and other promising tumor markers are being investigated. Although no marker has yet replaced the need to perform cystoscopy and cytology, the new tests can minimize the cost and difficulty of screening and long-term surveillance of patients who have or are at risk for bladder cancer.
References
-
- Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7–33. - PubMed
-
- Messing EM, Young TB, Hunt VB, et al. Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology. 1995;45:387–396. - PubMed
-
- Kroft SH, Oyasu R. Urinary bladder cancer: Mechanisms of development and progression. Lab Invest. 1994;1:158–174. - PubMed
-
- Henry NM. Natural history of bladder cancer. Urol Clin North Am. 1992;19:429. - PubMed
-
- de Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology. 1998;12:1717–1723. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources